Pilot study of fludarabine (F), cyclophosphamide (C), and amifostine (A) (FCA) in patients with chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Keating, AR [1 ]
O'Brien, SM [1 ]
Cortes, JE [1 ]
Thomas, D [1 ]
Koller, C [1 ]
Beran, M [1 ]
Kantarjian, HM [1 ]
Keating, MJ [1 ]
Giles, FJ [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1401
引用
收藏
页码：313A / 313A
页数：1
相关论文
共 50 条
  • [21] Oral fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukemia (CLL): Preliminary data.
    Cazin, B
    Binet, JL
    Divine, M
    Lepretre, S
    Lederlin, P
    Travade, P
    Lemaire, G
    Guibon, O
    BLOOD, 2000, 96 (11) : 515A - 515A
  • [22] The treatment of complicated and high risk chronic lymphocytic leukemia (CLL) with fludarabine, cyclophosphamide and rituximab (FCR).
    Donthireddy, V
    Shurafa, MS
    Saleh, M
    Kamboj, G
    Wang, D
    Janakiraman, N
    BLOOD, 2005, 106 (11) : 341B - 341B
  • [23] TUMOR LYSIS SYNDROME (TLS) IN PATIENTS RECEIVING FLUDARABINE (F) FOR CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)
    FRAME, JN
    SORENSEN, JM
    QASHU, N
    VENA, D
    CHRISTIAN, M
    CHUN, HG
    CHESON, BD
    BLOOD, 1993, 82 (10) : A139 - A139
  • [24] Final results of lower dose fludarabine (F) and cyclophosphamide (C), and high dose rituximab (R), (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL)
    Tarhini, Ahmad A.
    Land, S.
    Pietragallo, L.
    Laman, A.
    Sulecki, M.
    Marks, S.
    Meisner, D.
    Schaefer, P. M.
    Foon, Kenneth A.
    BLOOD, 2007, 110 (11) : 606A - 607A
  • [25] Early results of modified fludarabine, cyclophosphamide, and rituximab (mFCR) for patients with previously untreated advanced chronic lymphocytic leukemia (CLL).
    Tarhini, A. A.
    Land, S.
    Lim, F.
    Kiefer, G. J.
    Pietragallo, L.
    Pinkerton, R. A.
    Sulecki, M.
    Meisner, D.
    Schaefer, P. M.
    Foon, K. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [26] Fludarabine (F), cyclophosphamide (C), and GM-CSF (FCGM) is effective in chronic lymphocytic leukemia (CLL) and low grade non Hodgkins lymphoma (LGNHL).
    Gregory, S
    Goh, YT
    Fuerst, MP
    O'Brien, T
    Giles, FJ
    BLOOD, 1998, 92 (10) : 277B - 277B
  • [27] Fludarabine (FAMP) and mitoxantrone therapy in chronic lymphocytic leukemia (CLL).
    OBrien, S
    Kantarjian, H
    Beran, M
    Robertson, IE
    Freireich, E
    Kornblau, S
    Koller, C
    Estey, E
    Lerner, S
    Keating, M
    BLOOD, 1996, 88 (10) : 2341 - 2341
  • [28] Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study
    Montillo, Marco
    Tedeschi, Alessandra
    Ricci, Francesca
    Zaccaria, Alfonso
    Crugnola, Monica
    Spriano, Mauro
    Spedini, PierAngelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    De Blasio, Angelo
    Vismara, Eleonora
    Morra, Enrica
    Petrizzi, Valeria Belsito
    BLOOD, 2010, 116 (21) : 595 - 596
  • [29] Cost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL)
    Hornberger, J. C.
    Reyes, C. M.
    Shewade, A.
    Friedmann, M.
    Chan, L.
    Gutierrez, H.
    Satram-Hoang, S.
    Lerner, S.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Phase-II-study of rituximab in combination with fludarabine in patients (pts) with chronic lymphocytic leukemia (CLL).
    Schulz, H
    Klein, SK
    Rehwald, U
    Reiser, M
    Ibach, S
    Aulitzky, WE
    Hensel, M
    Herold, M
    Huhn, D
    Knauf, U
    Hallek, M
    Diehl, V
    Engert, A
    BLOOD, 2001, 98 (11) : 364A - 364A
12345